Innovent Announces the First Patient Dosed in the Phase I/II Study of IBI351 (KRAS G12C inhibitor) in Patients with Advanced Malignant Tumors
SAN FRANCISCO and SUZHOU, China, Sept. 30, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced a phase I/II clinical study of KRAS G12C inhibitor IBI351 in Chinese patients with solid tumors (ClinicalTrials.gov, NCT05005234) completed...
2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy
Revolutionizing Treatments for Blood Cancers and Solid Tumors TAIPEI, June 16, 2026 /PRNewswire/ -- On June 16, the Tang Prize in Biopharmaceutical Science announced its 2026 laureates. Three leading scientists in the field of cellular immunotherapy, Drs. Steven A. Rosenberg, Michel Sadelain, and Carl H. June, have been named joint laureates "for the discovery and development of tumor-infiltrating lymphocyte...
Henlius Forecasts Profit in 1H 2023
Spurring a Seamless R&D, Manufacturing, and Commercialisation Positive Cycle SHANGHAI, July 3, 2023 /PRNewswire/ -- Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited comprehensive management accounts for the six months ended June 30, 2023, the company expects to turn into profits in the first half of 2023, achieving profitability for the first time...
New CAS BioFinder Discovery Platform empowers drug discovery scientists to reveal insights, drive innovation, and save time
Transformative new scientific information capabilities combine an unparalleled collection of curated science data with advanced predictive models to accelerate early-stage drug discovery innovation COLUMBUS, Ohio, May 21, 2024 /PRNewswire/ -- Today, CAS, a division of the American Chemical Society specializing in scientific knowledge management, announced the launch of the CAS BioFinder Discovery Platform™,...
LigoLab Applauded by Frost & Sullivan for Transforming Diagnostic Laboratories with its All-in-One Integrated LIS & RCM Platform
LigoLab's Laboratory Operating Platform drives profit and revenue, improves efficiency, and delivers holistic testing services across multiple segments in diagnostic laboratories SAN ANTONIO, Jan. 18, 2022 /PRNewswire/ -- Frost & Sullivan recently analyzed the North American Laboratory Information Systems Industry and recognizes LigoLab as the 2022 Competitive Strategy Leadership Award winner for improving the efficiency of diagnostic laboratories and transforming them into thriving businesses....
HKSH Medical Group Named Asia’s first Photon-Counting CT Simulator Reference Site, Bringing Global Impacts on Precision Medicine and Medical Imaging with Siemens Healthineers
HONG KONG, May 12, 2026 /PRNewswire/ -- HKSH Medical Group (HKSH) and global medical technology leader Siemens Healthineers today signed a collaboration agreement at the "Asia Summit on Global Health", establishing HKSH as Siemens Healthineers' first Photon‑Counting Computed Tomography Simulator (PCCT‑Sim) Reference Site in Asia. For driving the development of PCCT-Sim technology, HKSH is not only Siemens Healthineers' research...
Fosun Pharma’s Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million
SHANGHAI, Aug. 12, 2025 /PRNewswire/ -- On August 11, Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement with Expedition Therapeutics Inc.(Expedition) to grant Expedition the rights to develop, manufacture, and commercialize XH-S004, an orally administered dipeptidyl peptidase 1 (DPP-1) inhibitor independently developed by Fosun Pharma, in all regions globally except Chinese...
Global Cord Blood Corporation Announces Entry into Cell Therapy Market by Acquiring Cellenkos and Its Products Rights
HONG KONG, April 30, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, announced today that the Company will acquire 100% of Cellenkos, Inc ("CLNK") and the rights to develop and commercialize all of its existing and future...
Jin Medical CEO Fireside Chat
CHANGZHOU, China, Feb. 5, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ:ZJYL) ("Jin Medical", and together with all its subsidiaries, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment hosted a CEO Fireside Chat on February 2, 2026 where the CEO shared some insights into the Company's recent strategic priorities and long-term growth considerations. The following questions were prepared by...
Nona Biosciences Successfully Develops World’s First Language Model Trained on Fully Human Heavy-Chain-Only Antibodies
CAMBRIDGE, Mass., Sept. 16, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, today announced the development of HCAbLM, the world's first language model specifically trained on fully human heavy-chain-only antibodies (HCAbs). HCAbLM was built on a large-scale repertoire comprising 31.8 million...
